Convatec jumps 9% to top FTSE 100 after lifting full-year organic growth guidance
AJ Bell · · AI-summarised by FinFlash
Convatec shares rose 8.9% to 268.80p, the best performer on the FTSE 100, after the medical products group raised its 2026 organic revenue growth guidance, excluding InnovaMatrix, to 6.25%-7.00% from 5.5%-6.5%. Ten-month organic growth was 6.6%. Continence Care is now guided to mid-to-high single digit growth and Infusion Care to double digits. InnovaMatrix is expected to deliver only about $5 million of revenue this year.
So What?
The upgrade supports a rerating of UK medtech names; investors will watch whether accelerating Infusion and Continence demand can offset the InnovaMatrix wound-care disappointment into 2027.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.